vs
Esperion Therapeutics, Inc.（ESPR）与莱迪思半导体（LSCC）财务数据对比。点击上方公司名可切换其他公司
Esperion Therapeutics, Inc.的季度营收约是莱迪思半导体的1.2倍（$168.4M vs $145.8M），Esperion Therapeutics, Inc.同比增速更快（143.7% vs 9.3%），过去两年Esperion Therapeutics, Inc.的营收复合增速更高（10.6% vs 8.4%）
Esperion Therapeutics, Inc.是一家上市美国药企，专注开发用于降低低密度脂蛋白胆固醇的口服小分子药物苯哌多酸，公司总部位于密歇根州安娜堡，目前核心研发管线围绕这款降脂创新药物推进，深耕血脂异常治疗领域的创新药物开发。
莱迪思半导体是美国专注于低功耗现场可编程门阵列（FPGA）设计制造的半导体企业，1983年成立，1989年上市，总部位于俄勒冈州希尔斯伯勒硅林区，在圣何塞、上海、马尼拉、槟城、新加坡等地设有运营网点，截至2022年员工超1000人，年营收超6.6亿美元。
ESPR vs LSCC — 直观对比
营收规模更大
ESPR
是对方的1.2倍
$145.8M
营收增速更快
ESPR
高出134.4%
9.3%
两年增速更快
ESPR
近两年复合增速
8.4%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $168.4M | $145.8M |
| 净利润 | — | $-7.6M |
| 毛利率 | — | 68.5% |
| 营业利润率 | 50.6% | 30.7% |
| 净利率 | — | -5.2% |
| 营收同比 | 143.7% | 9.3% |
| 净利润同比 | — | 14.6% |
| 每股收益（稀释后） | $0.32 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESPRLSCC
| Q1 26 | — | $145.8M | ||
| Q4 25 | $168.4M | — | ||
| Q3 25 | $87.3M | $133.3M | ||
| Q2 25 | $82.4M | $124.0M | ||
| Q1 25 | $65.0M | $120.2M | ||
| Q4 24 | $69.1M | $117.4M | ||
| Q3 24 | $51.6M | $127.1M | ||
| Q2 24 | $73.8M | $124.1M |
净利润ESPRLSCC
| Q1 26 | — | $-7.6M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $2.8M | ||
| Q2 25 | $-12.7M | $2.9M | ||
| Q1 25 | $-40.5M | $5.0M | ||
| Q4 24 | — | $16.5M | ||
| Q3 24 | $-29.5M | $7.2M | ||
| Q2 24 | $-61.9M | $22.6M |
毛利率ESPRLSCC
| Q1 26 | — | 68.5% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 67.9% | ||
| Q2 25 | — | 68.4% | ||
| Q1 25 | — | 68.0% | ||
| Q4 24 | — | 61.1% | ||
| Q3 24 | — | 69.0% | ||
| Q2 24 | — | 68.3% |
营业利润率ESPRLSCC
| Q1 26 | — | 0.7% | ||
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | -1.2% | ||
| Q2 25 | 8.6% | 3.8% | ||
| Q1 25 | -34.0% | 5.8% | ||
| Q4 24 | -6.4% | -10.4% | ||
| Q3 24 | -31.0% | 5.9% | ||
| Q2 24 | 3.5% | 18.2% |
净利率ESPRLSCC
| Q1 26 | — | -5.2% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 2.1% | ||
| Q2 25 | -15.4% | 2.3% | ||
| Q1 25 | -62.2% | 4.2% | ||
| Q4 24 | — | 14.1% | ||
| Q3 24 | -57.2% | 5.7% | ||
| Q2 24 | -83.9% | 18.2% |
每股收益（稀释后）ESPRLSCC
| Q1 26 | — | $-0.06 | ||
| Q4 25 | $0.32 | — | ||
| Q3 25 | $-0.16 | $0.02 | ||
| Q2 25 | $-0.06 | $0.02 | ||
| Q1 25 | $-0.21 | $0.04 | ||
| Q4 24 | $-0.14 | $0.12 | ||
| Q3 24 | $-0.15 | $0.05 | ||
| Q2 24 | $-0.33 | $0.16 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $167.9M | $133.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-302.0M | $714.1M |
| 总资产 | $465.9M | — |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESPRLSCC
| Q1 26 | — | $133.9M | ||
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | $117.9M | ||
| Q2 25 | $86.1M | $107.2M | ||
| Q1 25 | $114.6M | $127.6M | ||
| Q4 24 | $144.8M | $136.3M | ||
| Q3 24 | $144.7M | $124.3M | ||
| Q2 24 | $189.3M | $109.2M |
股东权益ESPRLSCC
| Q1 26 | — | $714.1M | ||
| Q4 25 | $-302.0M | — | ||
| Q3 25 | $-451.4M | $706.4M | ||
| Q2 25 | $-433.5M | $687.0M | ||
| Q1 25 | $-426.2M | $707.9M | ||
| Q4 24 | $-388.7M | $710.9M | ||
| Q3 24 | $-370.2M | $703.5M | ||
| Q2 24 | $-344.2M | $698.8M |
总资产ESPRLSCC
| Q1 26 | — | $883.1M | ||
| Q4 25 | $465.9M | — | ||
| Q3 25 | $364.0M | $844.4M | ||
| Q2 25 | $347.1M | $808.6M | ||
| Q1 25 | $324.0M | $823.6M | ||
| Q4 24 | $343.8M | $843.9M | ||
| Q3 24 | $314.1M | $853.7M | ||
| Q2 24 | $352.3M | $827.5M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $45.2M | $57.6M |
| 自由现金流经营现金流 - 资本支出 | — | $44.0M |
| 自由现金流率自由现金流/营收 | — | 30.2% |
| 资本支出强度资本支出/营收 | 0.0% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $153.3M |
8季度趋势，按日历期对齐
经营现金流ESPRLSCC
| Q1 26 | — | $57.6M | ||
| Q4 25 | $45.2M | — | ||
| Q3 25 | $-4.3M | $47.1M | ||
| Q2 25 | $-31.4M | $38.5M | ||
| Q1 25 | $-22.6M | $31.9M | ||
| Q4 24 | $-35.0M | $45.4M | ||
| Q3 24 | $-35.3M | $44.0M | ||
| Q2 24 | $-7.2M | $21.9M |
自由现金流ESPRLSCC
| Q1 26 | — | $44.0M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $34.0M | ||
| Q2 25 | — | $31.3M | ||
| Q1 25 | — | $23.3M | ||
| Q4 24 | — | $39.7M | ||
| Q3 24 | $-35.5M | $39.4M | ||
| Q2 24 | $-7.3M | $14.8M |
自由现金流率ESPRLSCC
| Q1 26 | — | 30.2% | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 25.5% | ||
| Q2 25 | — | 25.2% | ||
| Q1 25 | — | 19.4% | ||
| Q4 24 | — | 33.8% | ||
| Q3 24 | -68.7% | 31.0% | ||
| Q2 24 | -9.9% | 11.9% |
资本支出强度ESPRLSCC
| Q1 26 | — | 9.3% | ||
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | 9.8% | ||
| Q2 25 | 0.0% | 5.8% | ||
| Q1 25 | 0.0% | 7.2% | ||
| Q4 24 | 0.0% | 4.9% | ||
| Q3 24 | 0.3% | 3.7% | ||
| Q2 24 | 0.1% | 5.8% |
现金转化率ESPRLSCC
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 16.86× | ||
| Q2 25 | — | 13.23× | ||
| Q1 25 | — | 6.35× | ||
| Q4 24 | — | 2.75× | ||
| Q3 24 | — | 6.12× | ||
| Q2 24 | — | 0.97× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
LSCC
暂无分部数据
